IKT - Inhibikase Therapeutics GAAP EPS of -$0.81 revenue of $3.1M March, 31 2022 05:02 PM Inhibikase Therapeutics Inc. Inhibikase Therapeutics press release (NASDAQ:IKT): FY GAAP EPS of -$0.81. Revenue of $3.1M (+342.9% Y/Y). For further details see: Inhibikase Therapeutics GAAP EPS of -$0.81, revenue of $3.1M